Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Merck's HIV Treatment Matches Gilead's Biktarvy in Phase 3 Trial, Advancing Islatravir's Potential

Merck's HIV Treatment Matches Gilead's Biktarvy in Phase 3 Trial, Advancing Islatravir's Potential

Merck & Co. has reported promising results from a phase 3 clinical trial for its investigational HIV treatment, positioning islatravir as a potential new anchor for antiretroviral therapy regimens. The combination of doravirine and islatravir (DOR/ISL) demonstrated noninferiority to Gilead Sciences' Biktarvy, a current standard of care, in treatment-naive adults with HIV-1.

NoahAI News11/19/2025
Galapagos Exits Cell Therapy, Seeks New Direction Under Gilead's Watchful Eye

Galapagos Exits Cell Therapy, Seeks New Direction Under Gilead's Watchful Eye

Belgian biotech Galapagos is undergoing a significant strategic shift, abandoning its cell therapy ambitions and seeking new opportunities in the pharmaceutical landscape. The company's recent turbulence, marked by leadership changes and scrapped plans, highlights the challenges faced by mid-sized biotechs in a rapidly evolving industry.

NoahAI News11/19/2025
GSK Expands Oncology Pipeline with $50M LTZ Therapeutics Deal for Myeloid Cell Engagers

GSK Expands Oncology Pipeline with $50M LTZ Therapeutics Deal for Myeloid Cell Engagers

GlaxoSmithKline (GSK) has entered into a partnership with LTZ Therapeutics, signaling its entry into the emerging field of myeloid cell engagers. The deal, announced on November 19, 2025, involves an upfront payment of $50 million and positions GSK alongside other pharmaceutical giants in this promising therapeutic modality.

NoahAI News11/19/2025
Arrowhead Pharmaceuticals Secures First FDA Approval for FCS Treatment, Faces Competition from Ionis

Arrowhead Pharmaceuticals Secures First FDA Approval for FCS Treatment, Faces Competition from Ionis

Arrowhead Pharmaceuticals has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approval of Redemplo (plozasiran), marking the company's transition into a commercial-stage entity. The approval of this small interfering RNA (siRNA) therapy for familial chylomicronemia syndrome (FCS) represents a breakthrough in treatment options for this rare genetic disorder. However, Arrowhead faces immediate competition from Ionis Pharmaceuticals' Tryngolza in an increasingly contentious market.

NoahAI News11/19/2025
FDA Leadership Shakeup: Pazdur Takes Helm at CDER Amid Agency Turmoil

FDA Leadership Shakeup: Pazdur Takes Helm at CDER Amid Agency Turmoil

In a significant development for the pharmaceutical industry, Dr. Richard Pazdur has been appointed as the new head of the FDA's Center for Drug Evaluation and Research (CDER). This move comes amid a period of unprecedented turnover and internal strife at the agency, particularly between CDER and the Center for Biologics Evaluation and Research (CBER).

NoahAI News11/19/2025
Merck's Winrevair Shows Promise in Underserved Pulmonary Hypertension Indication

Merck's Winrevair Shows Promise in Underserved Pulmonary Hypertension Indication

Merck's activin blocker Winrevair continues to demonstrate its potential as a leading treatment for pulmonary hypertension, with new mid-stage data showing significant benefits for patients with combined post- and precapillary pulmonary hypertension (CpcPH).

NoahAI News11/19/2025
Genmab Streamlines Portfolio, Discontinues Two ADCs from ProfoundBio Acquisition

Genmab Streamlines Portfolio, Discontinues Two ADCs from ProfoundBio Acquisition

Genmab, the Danish pharmaceutical company, has recently made significant changes to its drug development pipeline, particularly concerning assets acquired from ProfoundBio in a $1.8 billion deal last year. The company has discontinued two antibody-drug conjugates (ADCs) while maintaining focus on its lead candidate from the acquisition.

NoahAI News11/19/2025
Nxera Pharma Announces Restructuring and Pipeline Refocus in Profitability Push

Nxera Pharma Announces Restructuring and Pipeline Refocus in Profitability Push

Nxera Pharma, formerly known as Sosei, has unveiled a comprehensive restructuring plan aimed at enhancing its path to profitability and achieving its 2030 growth and revenue targets. The Japanese pharmaceutical company will lay off 15% of its workforce and reprioritize its pipeline to focus on obesity, metabolic, and endocrine diseases.

NoahAI News11/19/2025
Jazz and Zymeworks' Ziihera Shows Promising Results in Gastroesophageal Cancer Study

Jazz and Zymeworks' Ziihera Shows Promising Results in Gastroesophageal Cancer Study

Jazz Pharmaceuticals and Zymeworks have announced positive results from their Phase III HERIZON-GEA-01 study, evaluating the efficacy of their HER2 bispecific antibody, Ziihera, in patients with gastroesophageal adenocarcinoma (GEA). The study's outcomes have been hailed as "practice-changing" by industry analysts, potentially positioning Ziihera as a new standard of care in first-line treatment for HER2-positive GEA.

NoahAI News11/19/2025
Pharmaceutical Industry Faces Widespread Layoffs and Strategic Shifts Amid Market Challenges

Pharmaceutical Industry Faces Widespread Layoffs and Strategic Shifts Amid Market Challenges

The pharmaceutical industry is undergoing significant restructuring as companies across the sector implement cost-cutting measures, primarily through workforce reductions. This trend reflects ongoing challenges in the market, including funding constraints, pipeline reprioritization, and the need for operational efficiency.

NoahAI News11/19/2025
Former FDA Commissioner Scott Gottlieb Joins UnitedHealth Group's Board

Former FDA Commissioner Scott Gottlieb Joins UnitedHealth Group's Board

UnitedHealth Group, a leading healthcare company, has announced the appointment of Dr. Scott Gottlieb to its board of directors. This strategic move brings together one of the most influential figures in U.S. healthcare policy with one of the industry's largest corporations, potentially shaping the future of healthcare delivery and innovation.

NoahAI News11/19/2025
Bidding War Heats Up as Lundbeck Makes $2.4B Offer for Avadel Pharmaceuticals

Bidding War Heats Up as Lundbeck Makes $2.4B Offer for Avadel Pharmaceuticals

In a surprising turn of events, Danish pharmaceutical company Lundbeck has entered the fray with a $2.4 billion buyout offer for Avadel Pharmaceuticals, potentially derailing the previously announced acquisition by Alkermes. This latest development has set the stage for a high-stakes bidding war in the pharmaceutical industry, with narcolepsy treatments at the center of the competition.

NoahAI News11/19/2025
«1...323334...67»